| Date | Title | Description |
| 14.03.2024 | Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline | Andera Partners’ portfolio company Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life Sciences and Nextech Invest Ltd, on be... |
| 14.03.2024 | Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca | Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire... |
| 28.02.2024 | Andera Partners raises a final amount of € 233 million for Andera Smart Infra 1, its first fund dedicated to renewable energy transition | The fundraising of Andera Smart Infra 1 highlights the strong interest of investors (including the European Investment Fund under InvestEU) in green infrastructure, resulting from renewable energy and ecological transition requirements.
Thi... |
| 21.02.2024 | MMI Raises $110 Million in Series C Financing | The funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced te... |
| 12.02.2024 | 2023 Report – After a record year of investments and exits, Andera Partners sets a target of 7 to 8 billion Euros in AUM by 2028 and announces its European ambitions | Andera Partners, a leading private equity investment firm, had a particularly active 2023, with €627 million deployed (+25% as compared with 2022), €790 million in sales proceeds (+53%) and €680 million in new funds raised.
Through its six ... |
| 12.02.2024 | Internship Offer – Andera Life Sciences | Andera Life Sciences, part of Andera Partners, is one of the leading Life Sciences venture capital teams in Europe and manages funds investing in therapeutics and medical devices. Through its Biodiscovery 6 fund, the team currently invests ... |
| 24.01.2024 | Meogroup initiates a new development cycle with the support of Andera Partners | Since its inception by Richard Caron in 2005, Meogroup has specialised in providing operational support to its clients in their performance challenges. Based in France and present in Europe (Belgium, Italy, Spain, Switzerland, Luxembourg) a... |
| 23.01.2024 | Andera Partners welcomes Sophie ELKRIEF as Business Development Partner | Sophie ELKRIEF has worked her entire career in the financial sector. She started in investment banking (1996-2001) in London and New York (Salomon Smith Barney, JP Morgan) prior to moving to asset management firstly with Dexia Asset Managem... |
| 18.01.2024 | Mistertemp’ group announces the reorganization of its shareholding: Andera Partners succeeds Montefiore Investment | Established in 2009 and based in Paris, Mistertemp’ group provides a multichannel offer of HR services (temporary work and recruitment) in France and in Europe. The group initiated a radical change to its market based on an approach combini... |
| 21.12.2023 | Spanish energy transition developer INGENOSTRUM accelerates, with a fund raising of 25M€ from Andera Partners | The expert in renewable energy project development |
| 14.12.2023 | The Efor Group joins forces with the Nodarius Group, which includes the Altogen brand, to strengthen its position as a European leader in specialized life sciences consulting. | Driven by its dynamism and market recognition, the group aims to extend its international scope, particularly in Europe and the USA, invest in the development of its offerings and expertise, and reach 5,000 employees by 2028. Its strategy w... |
| 05.12.2023 | The Imagerie Cardinet Group strengthens its position to accelerate its entrepreneurial model | Established in 1980, Imagerie Cardinet is a medical imaging group operating in Ile-de-France. The group provides complete healthcare services, with a recognised specialty in imaging for women, couples and children. Based on its dynamic grow... |
| 30.11.2023 | mylight150 secures €100m to accelerate the expansion of its solar self-consumption & smart energy management solutions in Europe. | The leader in solar self-consumption solutions |
| 14.11.2023 | Andera Partners co-leads a €67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom | Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf ... |
| 13.11.2023 | Andera Partners joins forces with Founders of Gosto Group in providing support in their international development on commercial furniture market | Established in 1998 in Wasquehal, the Gosto Group is a multichannel distributor of commercial, office and warehouse furniture, marketed via twelve owner websites including Gosto.com or Espace Equipement ; and directly via its physical showr... |
| 27.10.2023 | JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints | The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint. Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA) during the opening Late-Breaking Clinic... |
| 11.10.2023 | Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline | Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaa... |
| 10.10.2023 | ELAN Languages acquires Dutch company AVB Vertalingen | ElaN Languages, which has a turnover of around €30m following the June 2023 acquisition of Lingua-World in Germany, has built up a solid reputation for the quality of its services to a highly demanding clientele, including the Belgian and G... |
| 05.10.2023 | Andera Acto supports EFOR’s ambition of becoming a global leader in its market within five years | Since its inception, EFOR has demonstrated continuous growth exceeding 20% per year in a resilient market, in full globalization and in search of trusted players to outsource strategic activities throughout the product life cycle, requiring... |
| 05.10.2023 | Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial | Agomab Therapeutics NV (‘Agomab’) announces that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). In addition, Agomab has ... |
| 04.10.2023 | Andera Partners completes full exit from Travelsoft Group and hands over to CAPZA | - |
| 18.09.2023 | Andera Partners increases the hard cap for Andera MidCap 5 and raises a final amount of €750 million | This fundraising success highlights the strong interest investors have in the deep and resilient European and French Lower-Mid Market, as well as in the change of scale strategy led by Andera MidCap which has already delivered solid perform... |
| 24.07.2023 | Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours | Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the additi... |
| 11.07.2023 | 2022 Sustainability Report | For the first year, Andera Partners has published a Sustainability strategy covering responsible investment, climate, biodiversity, inclusion and value sharing. |
| 06.07.2023 | PAI Partners to acquire majority stake in Infra Group | PAI Partners (“PAI”), a pre-eminent private equity firm, today announces its agreement to acquire a majority stake in Infra Group, a multi-disciplinary network infrastructure services provider. Upon completion, PAI will become the largest s... |
| 04.07.2023 | ELAN Languages completes acquisition of German group Lingua-World GmbH | ElaN Languages, which has a turnover of around €20m, has built up a solid reputation over the past 30 years for the high quality of its services to a highly demanding clientele, including the Belgian national and regional governments, the E... |
| 29.06.2023 | Andera Acto supports Auris Group in restructuring of its capital and in its development strategy | Paris, 29 June 2023 – |
| 27.06.2023 | Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections | Allecra Therapeutics (“Allecra”) announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cefepime/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cef... |
| 19.06.2023 | Siparex ETI finalises agreement to become majority shareholder of Passman group | Passman, leader in networks management and digital solutions for hospitality establishments, will open up its capital to Siparex ETI as a new majority shareholder, allowing LBO France to exit. Andera Partners, the historic shareholder, will... |
| 14.06.2023 | Andera Partners and Pauwels Consulting management team join forces to accelerate the development of the group | Founded in 1999 by its CEO Bert Pauwels, Pauwels Consulting has achieved a leading market position as a consulting and staffing company focused on high skilled profiles to address Life Sciences, IT, and Engineering white collar niches. With... |
| 01.06.2023 | Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals | Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication of the results of two phase 2 clinical studies in the The Lancet Respiratory ... |
| 15.05.2023 | Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases | Andera Partners co-leads a €40 million Series A financing of Dualyx NV, a Ghent, Belgium based biotech developing next generation immune modulators. Alongside Andera, Fountain Healthcare Partners and Forbion co-led the round, with support f... |
| 10.05.2023 | Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets | Accelerating its ambitions in the German, Austrian and Swiss (DACH) region, Andera Partners is pleased to announce the appointment of Stefan Keitel as Senior Advisor. Mr. Keitel joins Andera Partners, a leading European private equity firm,... |
| 25.04.2023 | OneXillium group partners with Andera Acto to support them in their next development cycle | Established in 1989 and based in the Netherlands in Woerden, OneXillium has since the outset acted as one of the principal partners of Xerox in the Netherlands and in Europe. Later and through acquisitions, its business was extended to othe... |
| 20.04.2023 | Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients | Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs). |
| 18.04.2023 | Andera Partners co-leads a Series A extension round of € 47.75 million for radiopharmaceutical company Ariceum Therapeutics | Andera Partners, a leading European private equity player, today announces the successful completion of a Series A extension financing, co-led with Earlybird Venture Capital, for Ariceum Therapeutics (Ariceum), a radiopharmaceutical special... |
| 13.04.2023 | Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix® | Andera Partners, a leading European private equity player, today announces that it is leading a $48.5 million Series A financing round for medical device company BioVentrix, Inc. BioVentrix is developing minimally invasive therapies to dire... |
| 05.04.2023 | BEA Group (Andera Acto) expands in Italy, through acquisition of Capanna | PARIS, 5 april 2023 – BEA Group, supported by Andera Partners, announces the acquisition of the Capanna Group, a historic player on the Italian insurance market specialised in disaster recovery expertise for Italian and European insurers. D... |
| 29.03.2023 | Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours | Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced dosing of the first patient in the initial monotherapy module of ... |
| 22.03.2023 | Andera Acto supports SPS Group, a member of the ECF network, in its capital restructuring | PARIS, 22 MARCH 2023 – Advised by Crédit Agricole Midcap Advisors, the shareholders of SPS are undertaking a capital restructuring around its managing director, Mr. Frédéric Filippi and his team with the support of Andera Partners, a first-... |
| 15.03.2023 | Andera Partners co-leads $25m extension round for FIRE1 | Andera Partners, a leading European private equity player, today announces a $25m extension round, co-led with Novo Holdings, for Irish medtech company, FIRE1 Ltd. The financing provides FIRE1 with capital to accelerate the development of i... |
| 15.03.2023 | NG Travel Group chooses Andera Acto to support them in their capital restructuring | PARIS, 15 MARCH 2023 – Olivier Kervella, director of NG Travel, and his management team chose Andera Acto, the team responsible for the sponsorless mezzanine strategy of Andera Partners, to support the Group in the next phases of its develo... |
| 03.03.2023 | Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology | Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company. The combined company will advance Flamingo’s... |
| 01.03.2023 | Redslim partners with Andera Acto to support them in their next development cycle
Redslim partners with Andera Acto to support them in their next development cycle | - |
| 16.02.2023 | 2022 Report – Andera Partners | Andera Partners, a leading European private capital investment firm was particularly active in 2022 with 501M€ deployed, 515M€ of divestment proceeds and 758M€ successfully raised, representing a sharp increase compared to 2021. Through its... |
| 13.02.2023 | Andera Partners Portfolio Company Mineralys Therapeutics Successfully Completes Upsized $192 Million Nasdaq IPO | Andera has co-led the company’s $118 million Series B financing in June 2022 and re-invested into the oversubscribed IPO financing. |
| 02.02.2023 | Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease | Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the tre... |
| 26.01.2023 | Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics | Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced the closing of an oversubscribed $49 million Series B financing. ... |
| 23.01.2023 | Andera Partners reaches its €600 million target for Andera MidCap 5 | This fundraising success highlights the strong interest investors have in Andera MidCap’s change of scale strategy which has already delivered solid performances in prior funds. The first 15 exits completed by Winch Capital 3 and Winch Capi... |
| 10.01.2023 | Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension | SoniVie Ltd. (“SoniVie” or the “Company”), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million series C round financing. The financing was led by Andera Partners,... |
| 09.01.2023 | Andera Partners participates in the $138 Million Series C Financing of Amolyt Pharma | Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the closing of a €130 million (approx. $138M) Series C equity financing. The financing was led by Sofinn... |
| 14.12.2022 | Andera Partners opens its Milan office | (To read the press release in Italian, please click here) |
| 25.10.2022 | KLUBB Group acquires Isoli S.p.A. | Founded in 1946 and headquartered in Fontanaviva (near Padova), Isoli represents a reference player in the aerial work platform and tow truck market – renowned worldwide for its quality, reliability and innovative approach, boasting a state... |
| 20.10.2022 | T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial | San Francisco, CA and Berlin, Germany – October 20, 2022 – T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer... |
| 13.10.2022 | Andera Partners invests in a high-performance detection solutions company Senstronic | Founded in 1986 by Rémi Kirchdoerffer and headquartered in Saverne, France, Senstronic is a leading global designer and manufacturer of high-performance detection solutions. The Group offers sensors and connectors mainly used in industrial ... |
| 10.10.2022 | Andera Partners raises its largest life sciences fund at €456M, demonstrating the attractiveness of its activity and of the sector | The sixth generation of BioDiscovery funds is consolidating Andera Partners’ position as one of the leading players in life sciences venture capital in Europe. Existing institutional investors of the BioDiscovery funds have chosen to renew ... |
| 10.10.2022 | New governance for Andera Partners | Andera Partners is renewing its two main governance bodies: |
| 04.10.2022 | Ozitem chooses Andera Acto to support them in their capital restructuring | PARIS, 4 OCTOBER 2022 – François Espieux, director of Ozitem, and his management team have chosen Andera Acto (sponsorless franchise of Andera Partners) to provide support to the Group in the next phases of its development and to significan... |
| 03.10.2022 | Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine | LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering clinical-stage genomic medicine company, today announced that it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio. The proposed acqu... |
| 16.09.2022 | JenaValve Completes Enrollment in the ALIGN-ARIDE Clinical Trial | The ALIGN-AR trial is a landmark prospective, single-arm investigation device exemption (IDE) study designed to assess the safety and efficacy of the Trilogy Heart Valve System in high-risk patients with symptomatic, severe aortic regurgita... |
| 15.09.2022 | TRiCares Raises €47m in a First Closing of its Series C | The proceeds of this financing will primarily be used to continue the development of the company’s transfemoral tricuspid heart valve replacement system (“Topaz”) up through to the application for a pivotal investigational device exemption ... |
| 12.09.2022 | Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022 | Agomab is a Belgian-headquartered biotech company developing a portfolio of unique small molecule compounds and antibodies that address the transforming growth factor beta (TGF-ß) and hepatocyte growth factor (HGF) pathways. Growth factor p... |
| 30.08.2022 | Maritim Mobility | In January 2022, Maersk Supply Service, a subsidiary of Danish shipping giant Maersk, is launching Stillstrom – an offshore vessel-charging venture to support the decarbonization of the maritime industry by eliminating idle emissions. |
| 30.08.2022 | Heat, the forsaken vector of a renewable future | In the quest for a carbon neutral future, renewable energies thrust the spotlight. At the French level, ambitious programs are set in place, for massive offshore development or a renewing of the nuclear facilities. |
| 30.08.2022 | Green hydrogen will fuel tomorrow’s economy | In a context of dire instability of the oil prices, green hydrogen appears as a beacon of hope for an affordable, sovereign and decarbonated energy. Even if the market and the underlaying technologies have not reached their maturity yet, it... |
| 30.08.2022 | Datacenters | With the European data act proposed in February 2022, the Commission aims to make more data available for use, and set up rules on who can use and access what data for which purposes across all economic sectors in the EU. |
| 30.08.2022 | French electric vehicle charging points market | 1. Commercial road transport sector |
| 20.07.2022 | Medical Microinstruments Secures $75M to Advance Robotic Microsurgery | Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing. Deerfield Management led the round with... |
| 13.07.2022 | Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M | Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million. Pfizer led the extension wi... |
| 07.07.2022 | Andera Partners strengthens its Life Sciences team with a new partner | Andera Partners strengthens its organization by welcoming Jan Van den Bossche as a partner within Andera Life Sciences, its team specialized in innovative therapeutics and medical devices. |
| 05.07.2022 | Internship – Infrastructure Investment | About Andera Partners :
Created in 2001, Andera Partners is a major player in private company investments in France and internationally. Its teams manage nearly €3.2 billion in investments in life sciences (Andera Life
Sciences), growth and... |
| 04.07.2022 | Annual CSR Report 2021 / Rapport Annuel RSE 2021 | As an active investor with a 20-year track record of transforming the companies we invest in, Andera Partners must now be a major contributor to the challenges posed by climate change and the biodiversity crisis. Our ambition for sustainabl... |
| 13.06.2022 | ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Imm... | ImCheck Therapeutics announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million – USD 86 Million) and the last outstanding tranche of Series B conve... |
| 08.06.2022 | Andera Partners co-leads $118 Million Oversubscribed Series B Financing of Mineralys Therapeutics to Advance the Development of Novel, Targeted Treatment for Hypertension | Andera Partners, a leading European private equity player, announced today that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118 million Series B financing for Mineralys Therapeutics, Inc., a private, ... |
| 17.05.2022 | TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Canada | Heart valve diseases are among the most serious cardiac conditions, affecting more than 12.7 million patients in Europe and many more worldwide. In the last decade minimally invasive catheter-based solutions have been developed for other he... |
| 13.05.2022 | Andera Partners announces the intermediate closing of its new fund Andera MidCap 5 at €450m | Andera Partners – a leading private equity player focusing on small- and mid-sized growth companies in France and internationally – has announced the first closing at €450m of its fund Andera MidCap 5, the successor to Winch Capital 4 (€445... |
| 11.05.2022 | HR Path receives €225 million in Financing | HR Path today announced a new record round of financing. With this new operation, HR Path intends to continue its international expansion and strengthen its status as a global leader in the HR industry. |
| 03.05.2022 | Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs | Andera Partners, a leading European private equity player, through its biotech and medtech practice Andera Life Sciences, announced today that it is leading a €60 million (USD $63 million) Series B financing round for Tubulis with participa... |
| 27.04.2022 | Andera Partners to support ElaN Group, the leading technology platform for translation services in the Benelux, in its expansion in France and Europe | Andera Partners – a leading player in the field of small cap private equity through its vehicle Andera Expansion – takes a majority stake in ElaN Group, one of Belgium’s leading providers of specialised translation services and customised l... |
| 26.04.2022 | Successful first in human implantation of Topaz Tricuspid Heart Valve Replacement System | - |
| 07.04.2022 | Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer | Under the agreement, ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics, with an initial focus on treating respiratory syncytial virus (RS... |
| 01.04.2022 | Andera Partners and Compagnie Lebon launch a co-investment activity | Andera Partners, a leading independent asset management firm operating in private equity, has launched a co-investment fund, Andera Co-Invest. One year after the launch of Andera Infra, the creation of this sixth activity enables the asset ... |
| 31.03.2022 | Andera Partners announces two promotions to Partner and several appointments to strengthen its teams | MARIANNE HARLÉ has been promoted to Partner in the Andera Croissance team at Andera Partners, which she joined in 2017 as Director in the Andera Expansion team. She previously worked at TCR Capital from 2007 to 2017, after starting her care... |
| 22.03.2022 | Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers | Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunte... |
| 25.02.2022 | Andera Life Sciences is recruiting an Investment Director | Andera Life Sciences team is looking to hire an Investment Director as of March 2022. |
| 24.02.2022 | Andera Partners creates Andera Partners Transformation A unique support platform in private equity in France | The independent investment company dedicated to growth SMEs and mid-caps in France and abroad has announced the creation of Andera Partners Transformation, an initiative involving all its various teams and aimed at providing its portfolio c... |
| 22.02.2022 | Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients | TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announces it has raised Series A financing of EUR 39 million to accelerate development of its lea... |
| 17.02.2022 | With nearly €550 million deployed, Andera Partners experienced a record year in 2021 | Andera Partners, a leading independent private equity asset management company through its five specialist teams, Andera Life Sciences, Andera Infra, Andera MidCap, Andera Expansion and Andera Acto, had an extremely busy year in 2021 with €... |
| 03.02.2022 | Andera Partners invests in green renewable hydrogen production company Lhyfe | Andera Partners, a leading private equity firm, is investing in Lhyfe – a producer and supplier of green hydrogen – through its new energy transition infrastructure business, Andera Infra, joining other major investors in the sector. The pu... |
| 19.01.2022 | JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited | “We are clearly excited about our new partnership with Peijia Medical and the opportunity to bring our innovative TAVR technology to potentially millions of patients in China.,” said John Kilcoyne, JenaValve’s CEO. “The capital raised assoc... |
| 13.01.2022 | Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe | ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA”), a specialty pharmaceutical company with a strategic focus on hospital medicines in Europe, and Allecra Therapeutics (“Allecra”) today announced that the companies have signed an exclusive licen... |
| 10.01.2022 | BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies | BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered a multi-target disco... |
| 09.12.2021 | Andera Partners announces 1st closing at €84m for Andera Smart Infra 1 | Andera Partners, a leading private equity player focusing on high-growth SMEs and mid-caps in France and internationally, has completed an initial €84 million fundraising for its Andera Smart Infra 1 fund. This success reflects investors’ s... |
| 22.11.2021 | Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology | Vifor Pharma and Sanifit Therapeutics, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the companies have entered into a definitive agreement. V... |
| 15.11.2021 | Andera Partners supports the Founder of ENACO Group in the acquisition of its entire share capital and gives it the means to continue its strong growth | With more than 200 employees based in the Lille metropolitan area, the Group has trained more than 36,000 students in France and abroad since its creation, with a very strong acceleration in the number of enrollments over the past 3 years. ... |
| 28.10.2021 | Agomab Therapeutics to Acquire Origo Biopharma | Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinicalstage biotechnology company developing organ-restricted small molecule dru... |
| 26.10.2021 | Andera Partners supports Exciva in a Series A to fight Alzheimer’s disease | Andera Partners – a leading private equity player – through its biotech and medtech activity Andera Life Sciences, is leading the €9 million Series A round of Exciva GmbH, a German clinical biotech company developing a novel therapeutic com... |
| 29.09.2021 | The role of private equity in the recovery in France and Europe: an opportunity for investors | CONTENTS |
| 16.09.2021 | Andera Partners leads Amolyt Pharma’s $80 million Series B alongside Sectoral Asset Management | Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has closed an $80 million Series B equity financing round. The financing was co-led by ... |
| 10.09.2021 | Andera Acto supports DP Software Group in its development strategy | The fundraising organized by UBS allows its founder and shareholder Patrice Silvère, while retaining almost all of the capital, to acquire the means necessary to accelerate his growth strategy for the DP Logiciels group. |
